SGLT2 Inhibitors for Diabetes May Protect Against AKI, Increase UTI Risk
Providers need to assess the benefit-risk profile of SGLT2 inhibitors for individual patients, and take steps to avoid unnecessary risks.
Providers need to assess the benefit-risk profile of SGLT2 inhibitors for individual patients, and take steps to avoid unnecessary risks.
Opioid prescribing has declined in recent years, but nonetheless remains high for the chronic kidney disease population.
The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout.
Treatment-related adverse events of any grade develop in the majority of patients who receive urologic cancer therapies based on immune checkpoint inhibitors, according to a study.
Findings from the observational study indicate that the benefits of continuing RAAS inhibitor use outweigh the risks in patients with nondialysis chronic kidney disease.
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
This is the first study to assess the effect of allopurinol initiation on mortality in patients with CKD and concomitant gout, according to investigators.
The researchers examined data from the National Health and Nutrition Examination Survey.
Except for rituximab, no increased risk seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy